Experimental cancer drug trial halted early

NCT ID NCT05450562

Terminated Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called SAR444200, alone or with other cancer treatments, in 33 adults with advanced solid tumors that had spread and were not responding to standard therapy. The main goals were to check safety and find the right dose. The trial was terminated early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOPLASM

Contacts and locations

Locations

Icahn School of Medicine at Mount Sinai- Site Number : 8400005

New York, New York, 10029, United States
Investigational Site Number : 1240001

Québec, Quebec, G1R 2J6, Canada
Investigational Site Number : 1240002

Toronto, Ontario, M5G 2M9, Canada
Investigational Site Number : 1560001

Shanghai, 200120, China
Investigational Site Number : 1560002

Wuhan, 430022, China
Investigational Site Number : 4100001

Seoul, Seoul-teukbyeolsi, 06351, South Korea
Investigational Site Number : 4100002

Seoul, Seoul-teukbyeolsi, 05505, South Korea
Investigational Site Number : 7020001

Singapore, 308433, Singapore
Investigational Site Number : 7020002

Singapore, 119074, Singapore
Investigational Site Number : 7020003

Singapore, 169610, Singapore
Lifespan Corporation- Site Number : 8400002

Providence, Rhode Island, 02903, United States
The University of Texas MD Anderson Cancer Center- Site Number : 8400003

Houston, Texas, 77030, United States
USC Norris Comprehensive Cancer Center- Site Number : 8400004

Los Angeles, California, 90033, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.